But there's a growing understanding that this linear relationship may not be
appropriate at lower doses, since both beneficial and detrimental effects have been reported.
Not exact matches
At an FDA advisory panel meeting in October 2016 to discuss
appropriate naloxone
dosing, Seamus Mulligan, chief executive of Adapt Pharma Inc., said that «
lower doses of naloxone may deliver too little naloxone, too late.»
The copay will likely be cheaper than an
at - home test; plus, if you're really
low, your doc can advise you on the
appropriate dose to keep you in the normal range, which may be higher than what over-the-counter supplements provide.